Stereotactic radiotherapy in patients with oligometastatic or oligoprogressive gynecological malignancies: a multi-institutional analysis.
Cem OnalMelis GultekinEzgi OymakOzan Cem GulerMelek Tuğce YılmazSezin Yuce SariBerna Akkus YildirimFerah YildizPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)
Patients with early detection of oligometastasis (≤12 months) and with complete response observed at the stereotactic body radiotherapy site had a better survival compared with their counterparts. Stereotactic body radiotherapy at the oligometastatic site resulted in excellent local control rates with minimal toxicity, and can potentially contribute to long-term survival.